A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.

@article{Fox2012ASO,
  title={A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.},
  author={Edward J. Fox and Harold C Sullivan and Suzanne K Gazda and Lukas Mayer and Lindsay O'Donnell and Kh Melia and Stephen L. Lake},
  journal={European journal of neurology},
  year={2012},
  volume={19 2},
  pages={307-11}
}
BACKGROUND Alemtuzumab (CD52-specific humanized monoclonal antibody) was found to be an effective therapy for treatment-naive patients with relapsing-remitting multiple sclerosis. OBJECTIVE Evaluate alemtuzumab's effects in patients with treatment-refractory relapsing-remitting multiple sclerosis. METHODS Forty-five relapsing-remitting multiple sclerosis patients who experienced ≥2 relapses during 2 years prior to the study entry whilst receiving interferon therapy were administered 24 mg i… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Neutropenia as a Complication of Tumefactive Demyelinating Disease: A Case Report.

PM & R : the journal of injury, function, and rehabilitation • 2018
View 4 Excerpts
Highly Influenced

Alemtuzumab for Multiple Sclerosis

Current neurology and neuroscience reports • 2016

Alemtuzumab for the treatment of multiple sclerosis

Therapeutics and clinical risk management • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Similar Papers

Loading similar papers…